Masthead

GeoMx® Protein Assays

Masthead

Helping Your Research

High-plex Spatial Proteomic Analysis

GeoMx Protein Assays enable quantitative, spatial analysis of 96+ proteins from a single FFPE or Fresh Frozen slide, vastly expanding the number of markers you can profile from a single tissue section compared to traditional immunohistochemical methods. All assays are validated for use in multiplex so you can focus on the biology of interest without wasting time troubleshooting assay performance. 

Ordering Screen to TMA Screen

How it Works

The assay relies upon antibodies coupled to photocleavable oligonucleotide tags designed for readout with nCounter® (≤96-plex) or NGS (over 100-plex) platforms. After hybridization of antibodies to slide-mounted tissue sections, the oligonucleotide tags are released from discrete regions of the tissue via UV exposure. Released tags are counted in a standard nCounter assay or sequenced using NGS, and counts are mapped back to tissue location yielding a spatially resolved digital profile of protein abundance.

All GeoMx® Protein Assays undergo extensive validation to ensure high quality GeoMx DSP data. Read more about GeoMx Antibody Validation in this white paper.

Product Information

GeoMx Protein Assays for nCounter
GeoMx Protein Assays for NGS
Customize your GeoMx Protein Assays
GeoMx Protein Assays for nCounter

Immuno-Oncology and Immunology

The Immune Cell Profiling Core contains 18 targets for broad cell profiling of human samples (17 targets for mouse) and includes necessary controls for all GeoMx DSP experiments. Up to 6 10-plex modules plus 10 custom targets can be added to select the content most relevant to your human and mouse research.

 

Neuroscience

The Neural Cell Profiling Core contains 20 targets designed for broad cell profiling of human samples (19 targets for mouse) and includes necessary controls for all GeoMx DSP experiments. Up to 6 10-plex modules plus 10 custom targets can be added to select the content most relevant to your human and mouse research.

GeoMx Protein Assays for NGS

Designed to profile 10’s-100’s of protein targets simultaneously with spatial resolution using NGS platforms and pipelines. Run the 4-plex GeoMx Protein Core for NGS, which includes necessary controls for GeoMx DSP experiments, with any selection of 10-plex modules.

*Panel offerings subject to change prior to commercial launch.

Customize your GeoMx Protein Assays

GeoMx Protein Assays can be customized with up to 10 antibodies through NanoString’s Protein Barcoding Service, or with up to 5 antibodies from Abcam. Learn more about our partnership with Abcam and choose from over 6,000 IHC-validated antibodies to customize a GeoMx protein assay directly from Abcam.

Related Resources

See All Resouces
Brochure/eBook GeoMx DSP – Brochure
Product Bulletin GeoMx IO & Immune Protein Assays for nCounter – Product Bulletin
Product Bulletin GeoMx Neuro Protein Assays for nCounter – Product Bulletin
Product Bulletin GeoMx Human Protein Assays for NGS – Product Bulletin
Whitepaper GeoMx Normalization-Protein – Whitepaper

Publications

View All Publications

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler

Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication.

Spatially organized multicellular immune hubs in human colorectal cancer.

Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals.

Comparison between non-pulmonary Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19.

We read with interest the study by Manuel et al showing that chronic immunosuppression could protect against severe COVID-19 in liver transplant patients. 1 Despite increased comorbidities, COVID-19 in liver transplant patients was not more severe than in non-transplant cohorts.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us